CGEM

Cullinan Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Michaelson JenniferChief Scientific Officer
$3.1k200 shares
SellMay 5, 2026
$15.58
--
Michaelson JenniferChief Scientific Officer
$114k7.8k shares
SellMay 5, 2026
$14.60
--
Michaelson JenniferChief Scientific Officer
$125k8k shares
SellMar 5, 2026
$15.68
--
Michaelson JenniferChief Scientific Officer
$25k1.8k shares
SellFeb 25, 2026
$14.14
--
Ahmed NadimDirector, Officer: President And CEO
$196k13.5k shares
SellFeb 24, 2026
$14.47
--
Jones Jeffrey AlanChief Medical Officer
$66k4.6k shares
SellFeb 24, 2026
$14.47
--

News

seekingalpha.comCullinan Therapeutics: Heading Toward Paydirtseekingalpha.comJun 11seekingalpha.comCullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcriptseekingalpha.comJun 10globenewswire.comCullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseasesglobenewswire.comJun 10globenewswire.comCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congressglobenewswire.comJun 6globenewswire.comCullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engagerglobenewswire.comMay 26